Durolane 3ml

Clinical Monograph: Durolane 3 mL (Stabilized Hyaluronic Acid)

1. Classification and Chemical Overview

• Active Composition: Each 3 mL pre-filled syringe contains 60 mg of non-animal derived sodium hyaluronate (20 mg/mL) stabilized using NASHA (Non-Animal Stabilized Hyaluronic Acid) technology.

• Therapeutic Class: Viscosupplement / Intra-articular joint lubricant.

• Regulatory Status: Prescription-only medical device/biological product, administered exclusively by a qualified healthcare professional via intra-articular injection.

2. Mechanism of Action and Pharmacodynamics

• Restoration of Synovial Viscoelasticity: Osteoarthritic joint fluid suffers from degradation of endogenous hyaluronic acid, losing its shock-absorbing and lubricating capabilities. Durolane replenishes this fluid to restore normal rheologic properties.

• Prolonged Mechanical Retention: The NASHA cross-linking technology creates a cohesive gel matrix that resists rapid enzymatic degradation and clearance, allowing for an extended intra-articular residency time and prolonged mechanical cushioning of articular cartilage compared to lower-molecular-weight or non-stabilized hyaluronans.

3. Approved Clinical Indications and Dosing Scope

• Indications: Treatment of pain in osteoarthritis of the knee and hip in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.

• Dosing Regimen (Single-Injection Course):

  • Unlike multi-injection viscosupplements, Durolane is administered as a single 3 mL injection per target joint per treatment course.

  • Strict aseptic injection technique is mandatory.

4. Pharmacokinetic Profile

• Local Retention: The stabilized sodium hyaluronate gel remains localized within the synovial joint capsule, where it provides mechanical support and pain relief.

• Clearance: Gradually broken down locally and metabolically cleared via standard systemic pathways over several months.

5. Physiological Effects and Adverse Event Spectrum

Local injection site reactions are the most frequently reported adverse events, reflecting transient joint irritation.

Adverse Reaction Profile

• Common ($\ge 1/100$ to $<1/10$): Transient pain, stiffness, swelling, warmth, or localized effusion at the injection site.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Injection site paresthesia, rash, pruritus, and minor joint discomfort.

• Rare / Severe (<1/1,000): Severe acute inflammatory reactions (pseudosepsis) characterized by marked joint swelling and pain requiring arthrocentesis; systemic hypersensitivity reactions (anaphylactoid responses).

6. Contraindications, Drug Interactions, and Clinical Precautions

Kontraindikationen

• Known hypersensitivity (allergy) to hyaluronan (sodium hyaluronate) preparations.

• Pre-existing infections, skin diseases, or active cutaneous or bacterial infections in the area of the injection site or the target joint.

Key Interacting Factors & Warnings

• Quaternary Ammonium Salts: Do not use skin disinfectants containing quaternary ammonium salts for joint preparation, as sodium hyaluronate can precipitate in their presence.

• Non-Avian Origin Advantage: Because Durolane is synthesized via bacterial fermentation using NASHA technology rather than extracted from avian sources, it carries no risk of hypersensitivity reactions related to chicken proteins, feathers, or eggs.

Clinical Precautions and Post-Injection Guidelines

• Effusion Management: Any significant joint effusion must be evaluated and aspirated prior to injecting Durolane.

• Activity Restrictions: Patients should be advised to avoid strenuous activities (such as high-impact sports, heavy lifting, or prolonged running) and excessive weight-bearing for approximately 48 hours following the injection.